Healthcare industry

The company Rentschler from Laupheim in the south of Germany is nowadays one of the biggest biopharmaceutical contract manufacturers in Europe. This has not always been the case. A look at the companys history shows why the company which is nowadays run by the third family generation has become what it is today.

Article - 28/04/2008

A milestone in the treatment of leukaemia

Blood cancer experts in the team of Professor Peter Dreger Head of the Section of Allogeneic Stem Cell Transplantation at the University Hospital of Heidelberg have achieved a major success in the treatment of leukaemia. For the 500th time the physicians from the Department of Haematology Oncology and Rheumatology transferred blood stem cells from a healthy donor to a patient suffering from leukaemia or lymphoma.

Dossier - 24/04/2008

Contract manufacture: the order books remain full

The market for therapeutic proteins is continuing to grow in double figures. Current estimates of the total market value are in the range of 60 to 70 billion US dollars and the market is estimated to grow by 13 per cent p.a. up until 2010. Biopharmaceutical contract manufacturers have established themselves on the market and market observers estimate that the number of biopharmaceutical medicines will grow from 100 2005 to approx. 150 until 2010.

In the second article in the series on the platforms successful cooperations BioValley presents an encouraging approach for improving the quality of life of severely ill cancer patients and the successful establishment of an industrial biochip platform.

The first European Conference for Clinical Nanomedicine is to be held soon in Basel. BIOPRO has therefore discussed this promising area of application with Beat Löffler and Dr. Patrick Hunziker the founders of the European Foundation for Clinical Nanomedicine.

Article - 16/03/2008

New indication for lead compound of Apogenix

Isolated tumour cells use to invade healthy brain tissue during the development and growth of glioblastoma multiforme GBM. This mechanism involves the CD95CD95L death system. These results supports the therapeutic potential of Apogenix APG101 for the treatment of glioblastomas.

Dr. Gilbert Gorr has been fascinated by the moss Physcomitrella patens for many years in fact it occupies a great deal of his waking moments. The enthusiasm with which the CSO of greenovation Biotech GmbH talks about the key object of his work is both intoxicating and contagious. The latest discovery The moss produces a therapeutic antibody that is far more effective than its predecessors created in animal cell cultures.

Young medical professionals or young scientists are eligible to apply for funding.

Article - 05/02/2008

Protecting the liver from oxygen stress

The Emmy Noether junior research group in the Department of Surgery at the University Hospital of Heidelberg is to be funded with 1.2 million over the next five years. The group will focus on how tissue damage in donor livers can be prevented. The group headed by Dr. Martin Schneider.

The Food and Drug Administration approved Nycomeds ALVESCO ciclesonide Inhalation Aerosol in the United States for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older.

Gender-specific differences are currently not only a subject of debate for experts but have also raised broad media interest. However there are very few specific investigations that are able to provide a clear answer said Prof. Volker Kühlkamp chief physician in the Department of CardiologyElectrophysiology at the Lake Constance Heart Centre in ConstanceKreuzlingen and specialist in cardiac arrhythmia.